Comparing Remimazolam and Propofol for Postoperative Anesthesia Satisfaction in Outpatient Gynecological Surgery: A Randomized Clinical Trial
Drug Design, Development and Therapy · 2024
DOI: 10.2147/dddt.s483029 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Drug Design, Development and Therapy, 2024. Verfasst von Xu-Lin Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of…. Hauptthemen laut MEDLINE: Propofol, Gynecologic Surgical Procedures, Patient Satisfaction. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
This study aimed to compare the efficacy of remimazolam and propofol regarding postoperative anesthesia satisfaction in patients undergoing outpatient gynecological surgery. Patients and Methods: This was a single-center, open-label, non-inferiority, randomized clinical trial. Patients aged ≥ 18 years who underwent outpatient gynecological surgery with sedation were enrolled. Participants were randomly assigned to be sedated with remimazolam or propofol. The primary endpoint was the immediate postoperative anesthesia satisfaction score, evaluated through the Iowa Satisfaction with Anesthesia Scale (ISAS).
Results
168 patients were randomly allocated to either the remimazolam group (n = 84) or the propofol group (n = 84). The mean (standard deviation) ISAS scores immediately after surgery were 1.7 (0.6) for the remimazolam group and 2.0 (0.7) for the propofol group (difference, -0.2; 97.5% confidence interval [CI]: -0.5 to -0.0; p = 0.02), indicating non-inferiority. The length of post-anesthesia care unit (PACU) stay was longer in the remimazolam group than in the propofol group (27.6 [9.1] min vs 22.4 [7.0] min; difference, 5.2 [95% CI: 2.7 to 7.6] min; p < 0.001). High-intensity injection pain was less frequently observed in the remimazolam group than in the propofol group (3.6% vs 45.2%; difference, -41.7% [95% CI: -54.2% to -29.1%]; p < 0.001). The nausea score was higher in the remimazolam group immediately after surgery than in the propofol group. Pain, nausea, sleep quality, anxiety, and depression scores were higher in the remimazolam group than in the propofol group on postoperative day 1. The incidence of adverse events and other secondary endpoints was comparable between the two groups.
Conclusion
Remimazolam was non-inferior to propofol regarding postoperative anesthesia satisfaction in patients undergoing outpatient gynecological surgery. Therefore, it should be considered as a new sedation alternative in such procedures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
- Department of Respiration, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Zitieren
APA
Wang, X. L., Dai, L. L., Li, Y. N., Zhang, J. W., Qu, M. C., Zhou, Y. Y., & Xing, N. (2024). Comparing Remimazolam and Propofol for Postoperative Anesthesia Satisfaction in Outpatient Gynecological Surgery: A Randomized Clinical Trial. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s483029
Vancouver
Wang XL, Dai LL, Li YN, Zhang JW, Qu MC, Zhou YY, et al. Comparing Remimazolam and Propofol for Postoperative Anesthesia Satisfaction in Outpatient Gynecological Surgery: A Randomized Clinical Trial. Drug Design, Development and Therapy. 2024. doi:10.2147/dddt.s483029
BibTeX
@article{Wang2024,
author = {Wang, Xu-Lin and Dai, Ling-Ling and Li, Yan-Na and Zhang, Jian-Wen and Qu, Ming-Cui and Zhou, Yao-Yao and Xing, Na},
title = {Comparing Remimazolam and Propofol for Postoperative Anesthesia Satisfaction in Outpatient Gynecological Surgery: A Randomized Clinical Trial},
journal = {Drug Design, Development and Therapy},
year = {2024},
doi = {10.2147/dddt.s483029}
}
EUVIMED